Tema Oncology ETF Rating $23.19 +0.61 (+2.70%) Closing price 04/17/2025 03:55 PM EasternExtended Trading$23.22 +0.04 (+0.15%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestTrendsBuy This Stock Tema Oncology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.81Holdings in CANC have an aggregate rating of Moderate Buy based on 606 analyst ratings issued in the past year covering 45 companies (85.7% of the portfolio).CANC Aggregate Price Target$23.19High Prediction$23.19Average Prediction$23.19Low Prediction$23.19Holdings in CANC have an aggregate price target of $23.19 and a range of $23.19 to $23.19 covering 45 companies (85.7% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy19 Buy rating(s)Moderate Buy22 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 45 CANC Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.33%LLYEli Lilly and Company$841.70+14.5%4.8316 of 5 stars2.89$1,012.00 20.2%19News CoverageGap UpHigh Trading Volume5.19%RHHBYRoche$38.90+0.8%N/A2.5065.08%RVMDRevolution Medicines$36.76+1.5%3.7155 of 5 stars3.00$66.67 81.4%124.68%BMYBristol-Myers Squibb$49.24-0.3%4.7337 of 5 stars2.32$57.67 17.1%19Upcoming EarningsShort Interest ↓Analyst RevisionNews CoveragePositive News4.24%EXELExelixis$36.19+0.1%4.2516 of 5 stars2.50$37.59 3.9%20Analyst ForecastPositive News4.14%BBIOBridgeBio Pharma$33.87+0.1%4.5998 of 5 stars2.92$53.00 56.5%12Analyst ForecastInsider TradeAnalyst RevisionNews Coverage3.81%NUVLNuvalent$71.64+2.4%1.7635 of 5 stars2.90$115.50 61.2%10Insider TradeNews CoveragePositive News3.50%ZLABZai Lab$28.84-0.3%2.8594 of 5 stars2.75$47.37 64.2%4Gap Up3.24%GMABGenmab A/S$20.04+2.5%4.2051 of 5 stars2.69$39.17 95.4%13Short Interest ↓Analyst RevisionGap Down3.11%AMGNAmgen$277.29-1.9%4.6085 of 5 stars2.48$314.91 13.6%23Analyst DowngradeAnalyst Revision2.98%MRUSMerus$43.06+2.7%2.9702 of 5 stars3.13$85.31 98.1%16Positive News2.95%MRKMerck & Co., Inc.$77.93+1.9%4.9993 of 5 stars2.64$115.50 48.2%22Upcoming EarningsAnalyst Forecast2.94%BPMCBlueprint Medicines$84.62+3.1%2.6722 of 5 stars2.70$124.95 47.7%23Analyst ForecastAnalyst RevisionNews Coverage2.92%SMMTSummit Therapeutics$24.61+6.8%2.8055 of 5 stars3.00$35.40 43.8%102.90%ONCBeigene$230.98+1.2%2.134 of 5 stars3.00$316.67 37.1%3Analyst ForecastInsider TradeGap Up2.86%ACLXArcellx$62.02+2.2%2.0646 of 5 stars3.14$110.67 78.4%14Positive News2.86%LEGNLegend Biotech$32.80-2.0%2.4521 of 5 stars2.92$79.00 140.9%12Analyst ForecastAnalyst RevisionNews CoveragePositive News2.12%ABBVAbbVie$172.78+0.6%4.9021 of 5 stars2.85$210.71 22.0%26Upcoming EarningsEx-DividendAnalyst ForecastAnalyst RevisionPositive News2.03%JANXJanux Therapeutics$29.69+3.5%2.7358 of 5 stars3.09$95.25 220.8%11Positive News2.02%GILDGilead Sciences$104.49-0.4%4.5373 of 5 stars2.72$105.12 0.6%29Upcoming EarningsInsider TradePositive News1.93%ARGXargenx$596.20+1.5%3.2801 of 5 stars2.91$699.28 17.3%23Analyst Forecast1.42%IDYAIDEAYA Biosciences$17.08+5.6%3.5545 of 5 stars2.93$53.58 213.7%151.07%REGNRegeneron Pharmaceuticals$563.16+2.5%4.8764 of 5 stars2.77$963.56 71.1%26Analyst ForecastNews CoveragePositive News0.99%DAWNDay One Biopharmaceuticals$6.84+1.2%2.7384 of 5 stars3.13$32.29 372.0%8Positive News0.98%NRIXNurix Therapeutics$10.24+4.5%2.3486 of 5 stars2.84$30.44 197.3%19Gap Down0.90%MREOMereo BioPharma Group$2.30+8.0%2.0593 of 5 stars3.25$7.71 235.4%8High Trading Volume0.84%CGONCG Oncology$20.64+2.1%1.2696 of 5 stars3.00$59.33 187.5%11Analyst ForecastNews CoveragePositive News0.76%ELVNEnliven Therapeutics$16.53+2.9%2.64 of 5 stars3.25$40.33 144.0%4Gap Up0.72%IMCRImmunocore$28.41+1.9%2.3885 of 5 stars2.54$63.73 124.3%130.71%GHGuardant Health$44.97-0.5%3.8147 of 5 stars3.05$49.00 9.0%210.68%LNTHLantheus$101.32+0.8%4.3471 of 5 stars3.00$129.43 27.7%7Positive News0.62%ZYMEZymeworks$11.53+2.5%2.7044 of 5 stars2.88$21.00 82.1%8Positive News0.59%COGTCogent Biosciences$4.37+2.3%2.4597 of 5 stars2.75$14.43 230.2%8Positive News0.52%INCYIncyte$58.21+0.8%4.8661 of 5 stars2.21$74.88 28.6%19Analyst Revision0.51%SDGRSchrödinger$25.75+2.1%2.5316 of 5 stars3.00$33.00 28.2%8Analyst ForecastInsider TradeNews Coverage0.50%CGEMCullinan Therapeutics$7.89+3.7%2.2332 of 5 stars3.00$34.80 341.1%6Analyst ForecastNews CoverageGap Down0.48%REPLReplimune Group$7.99+4.7%3.6026 of 5 stars3.13$19.43 143.2%80.45%ILMNIllumina$71.21-3.2%4.589 of 5 stars2.48$138.70 94.8%21Analyst RevisionGap Down0.41%SNDXSyndax Pharmaceuticals$11.51+4.1%3.3695 of 5 stars2.90$36.20 214.6%10Positive NewsGap Up0.41%ARVNArvinas$8.60+12.4%3.5847 of 5 stars2.69$34.33 299.2%16Analyst ForecastShort Interest ↓High Trading Volume0.34%ORICORIC Pharmaceuticals$4.77+1.7%3.4509 of 5 stars3.00$18.86 295.3%9Positive News0.31%RLAYRelay Therapeutics$2.69+3.1%2.7337 of 5 stars2.82$18.36 582.7%11Analyst ForecastNews CoveragePositive NewsGap Up0.25%AUTLAutolus Therapeutics$1.43+5.9%2.1363 of 5 stars3.00$9.32 551.7%6Positive News0.23%CELCCelcuity$10.24+2.5%1.3255 of 5 stars3.14$30.17 194.6%70.18%RCUSArcus Biosciences$7.89+0.4%2.3986 of 5 stars3.00$30.25 283.6%10 This page (NASDAQ:CANC) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
